# Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused

> **Open Intelligence Dossier** · First detected: 2026-09-01 06:07 UTC · Category: Business

## Executive Summary
Novartis and Bristol Myers Squibb halt multiple CAR-T clinical trials for autoimmune diseases following patient deaths and safety reviews.

## Intelligence Brief
Recent coverage from outlets including Reuters, Bloomberg, the Wall Street Journal, Barron's, BioSpace, BioPharma Dive, Fierce Biotech, Endpoints News, FirstWord Pharma, and GuruFocus details a major development in clinical research. Novartis has halted eight CAR-T clinical trials spanning immunology, neurology, and autoimmune diseases. This decision follows three patient deaths occurring within these studies. In tandem with the Novartis announcement, Bristol Myers Squibb has also paused its own CAR-T programs for lupus and other autoimmune conditions due to safety events and concerns. Reporting heavily emphasizes the scope of the clinical holds, which impact multiple active research pipelines focusing on severe autoimmune disorders.


Specialized life sciences publications like BioSpace, BioPharma Dive, Fierce Biotech, and Endpoints News tracked the unfolding sequence closely, noting that Bristol Myers Squibb followed the initial Novartis halt by pausing its related studies as well. General financial and business coverage from Bloomberg, Barron's, and the Wall Street Journal examined the broader market and corporate implications of these safety reviews, while outlets like GuruFocus and finance.biggo.com evaluated the financial positioning and stock movements of the companies involved. The context provided by the coverage centers on the experimental application of chimeric antigen receptor T-cell therapies outside of oncology, specifically targeting complex autoimmune and neurological conditions such as lupus. These trials represent a major frontier in drug development, shifting advanced cell therapies from cancer treatment into chronic immune-mediated diseases. However, the emergence of fatal safety events highlights the substantial clinical risks inherent in these investigative protocols, prompting immediate regulatory and corporate caution across major pharmaceutical developers.


Future developments will depend on the findings of the ongoing safety reviews initiated by the sponsoring companies. Coverage does not yet specify when the trials might resume or what specific adverse events triggered the safety reviews beyond the reported deaths. Observers are monitoring whether additional pharmaceutical firms with similar pipelines will implement precautionary pauses, and how regulatory authorities will respond to the safety data emerging from the halted studies.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| finance.biggo.com | Novartis Halts Eight CAR-T Trials After Three Patient Deaths | [Source Link](https://news.google.com/rss/articles/CBMidkFVX3lxTE5PTWJiSDNzYWxDeFRkNFhmX0ZVWWtTUnpMSmFMbThSenI3amdiNlVaSHRMaXRQaGtTZUZ3UmFHMXJtWngtVFRPRzNIc0JEVTJSZ1JUTVh2cnk3YnR2NDJwalJvcmV6OGNQVWtKVkoya2gyeUZXVWc?oc=5) |
| Lupus Foundation of America | Novartis, Bristol Myers Squibb pause CAR-T trials for lupus and other autoimmune diseases for safety reviews | [Source Link](https://news.google.com/rss/articles/CBMitAFBVV95cUxOU1dDSUp0ckRKZmhyWE82MndqWm42Z0FXZDB2X19ETmVLcjZHUkJRYk5ia0d0WFNCRkE4SGRZR25qN3JEeWN6M0c1MjkwMVNwcXhMVnNpczFteE5KQkNQUll4ajdTLW03R2NVOUdSVzRBNU55cktydnhWRl9vOWlHYXZucFN2c0czVnIzVFFHcW5JMGY0YnlwMzNzNkxXbm5yVUQ3VXZlaENHajJXMnJtRkpJU2c?oc=5) |
| BioSpace | Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety events | [Source Link](https://news.google.com/rss/articles/CBMiwgFBVV95cUxNTVg5TnhRV3BnZENvQXRkV1NFQ2QzUW1NVERoblBOS29ReG1KZDFHRkdqV2hFdGR0TTlsNkVCV29WZkplSXF2U3ZBN09Fb01ObUhqNWVOZDFqUHNmQ2hiYXo1QmFkQXlpOGNFY2dqVW12RHlVUVNjeGR6MDF6VkxGaHE4MzNNejE4bnVLQmQ4NXM1NDhsZUNJQ2laUlhqM1Z2NXdJZDJoZ0pZeUlFWjRoYTZlR0U1QmpQMU95V0tqWHZVZw?oc=5) |
| Barron's | Why Novartis Stock Is Heading for Its Best Day Since 2023 After 3 Patient Deaths | [Source Link](https://news.google.com/rss/articles/CBMihwFBVV95cUxNNHl6V0VHMERWR2VWQVVFYkl3RjdmWDhlVzlsVVBZNk13OG0zNWp6UEtKTTRhT0NmVlFMcTd4SEgtamRqa25wMGRzeTVRMXpEenlWel9DQzZRb0FxUGxMSVlKOXZOSzBzM3h3OGlEVUc2a3NfdzZRUXVlQ2Vfd1lCd21TZFl2blU?oc=5) |
| Reuters | Novartis pauses autoimmune cell therapy studies after deaths, WSJ reports | [Source Link](https://news.google.com/rss/articles/CBMi3AFBVV95cUxQdHJVWklEdmVwSjU0V2NiVjQyRjFpQUIwTGk4SVBaLXczMlA5Zk1rbFR2aEVzVzZIUG5pVkJ0QnRZSFF5NXdWczNrZ2JWRWFYQmZ3Wl9VUWd2Y3J0WndoWHpNSGJ3ZlVXNmJrOWFFckRoaTJZdV9oa0lCRllySlZPczVfWnZsNUttSTRWdWt2cFF6bUFiQm9vbW1RNzNZWlpzN0ljRnZnb0ZDNHdSRG1TZlVVdmFnTkNFcUdmdVJfZm1NQ1ktSEJXcS0wakFBdWJWRWlIZllPUEotazlG?oc=5) |
| Bloomberg.com | Novartis Pauses Autoimmune Drug Trials After Three Patients Die | [Source Link](https://news.google.com/rss/articles/CBMitAFBVV95cUxQRzc5UFN6TWs2RUxQMmNkUl9qeE5ObEkwZENIZzBZRDJKajhYTUFLZWlsNnlneWM0MmMtN1pyTk52Wjk3bzNpaXhZS0RPeGVBeGx6OTZuek1GME9fSk1nRUwtU3kwV0FmZkI5OW5yTmlYU1pBempVQUtFVHp3V1doUHRPakd6UFhkT0tRd0QwYlMxXzhqTHlEamJ5NTVLRHNjZjJ5Wm1uRzY2N2UwNW41THA3Tkc?oc=5) |
| GuruFocus | NVS Looks 16.5% Overvalued on GF Value™ Amid Dividend Safety Foc | [Source Link](https://news.google.com/rss/articles/CBMipAFBVV95cUxPNWFVZlAwMzA0dDFaZWJaMHhHbDRTNmRMWXR0Z1lUSlpwRGQ0WEduZ1NJSTNfRW1HemxyQUlHV0p5aG9ELXJSb2tYVGhBcFpIZ0tlUkQtVjRlaTgwYl9ERUMtN1RFSG14aWE1RHVwWHdLWkJQd2RDU0lXS255a3RMZVNERXNQYWdibG9FdFhsRDV5aDdfb0VpUUxkOHMySVQwSEFTcA?oc=5) |
| FirstWord Pharma | Novartis pauses immunology, neuro CAR-T studies after three patient deaths | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE4tQTVDYjdPXzZDWUY0WElrTGxOY3JHTzZaVG1SXzdBem10bFhIc1hiaF9fNU13aFFXMUh2aGtTWG9FbnRFX2Flc2gxS0FMa0lueHhn?oc=5) |
| WSJ | Novartis Pauses Autoimmune Cell Therapy Studies After Deaths | [Source Link](https://news.google.com/rss/articles/CBMipgFBVV95cUxPbmh5dlMwVjNZdlUyS181Uy01SWJRWHV4R2R3RGdELTVLeU9TOGUxVzhwTnRILU5hd3lnUVc2WVUyczcxN1FJeU9EdGdSaFJwb2xvd0N5bjRLSjNJcWJfRGlYa0hxWUxDMWhkSjZCLUxuLWQ3T0V0eXVuM2ZSdmduVFkyLTZzWmoxVTVRUjdIZjhMS2tpOGxONnJWOUhZLWJXYkdCUXdn?oc=5) |
| BioPharma Dive | Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns | [Source Link](https://news.google.com/rss/articles/CBMiogFBVV95cUxObjBCQUgxNnhlWERZU3l0U0NTb2lycy04TFFMdThBbHpHQ2JheWJnUGQ3OGppX3NTQ1FLeVpOQWpndDQ2OGlFZG84Y3M5djcyRDRhZmJmZldsajVRQXVKek50RUxDZ1ZPMkoydnB1NENDWjhObzJzdWZ4ZWJ1ZFBEbE9UOFQ4Z0NvTnJtRmg4NER2YUpKMk1sSDZCM1h2Q1FnVnc?oc=5) |
| Fierce Biotech | UPDATED: Novartis halts autoimmune CAR-T trials after 3 deaths, as BMS also pauses studies | [Source Link](https://news.google.com/rss/articles/CBMirAFBVV95cUxNbFVrYUVOcmRMeDFtRnFna0lnb01jN2JXYmlhZjJUR2pHMFhJMnUyQVA5eGxnWUNzVnVyRzFibFVKLVJmd3ZqR3V4cDdnOWdpWnV4bGQtSW5uUTJHdEpDYy15WUtUQVdXU0I4RDMyVy1GcWIyN3N4Vmw3M2xzR3lqLURPSWowb0ZRaUFBdHN5V2xycF9fSmF1Vzg0NGowNzlKaEVmZFVvcFVPMjBP?oc=5) |
| Endpoints News | Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused | [Source Link](https://news.google.com/rss/articles/CBMisAFBVV95cUxPeHhCY0p1WTdrYW43OTBid3plZ3hSQkpxUDFkUmJpam1PdFBNNHh3bnNxOVhkelR3RGFJYnAteXpQdklzU0d0S2lYVlhvNEZUMENtVUp4TjJPaEd4SUFiOGVpZDVYRXV0aXRhbnlfREJSRjJPaWIyU1ZSLTFMSWRZTUtZYUJMaWpzRVEwd1ZQTEFOOEI0ZTZFSjNBQ21RUkhBcUFrRmg5VXJ3blB5amR6Vw?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-09-01/three-deaths-in-car-t-trials-prompt-halt-by-novartis-bristol-myers-programs*